MDD logo ACS Publications
June 2004 From Concept to Development
About MDD
Volume 7, Issue 6
Article Indexes
Author Indexes


Animal models of diseaseAnimal models of disease
by Chaoyong Ma

PDF version (192 KB PDF)
In vivo assays are not usually performed until or after lead optimization is complete. This is partly due to the low speed and high cost of conventional animal models (typically rodents) and the relatively high number of preliminary hits from HTS. With alternative small-animal models emerging, however, it is now possible to perform in vivo testing earlier in the process. Thus, researchers have developed model systems using both invertebrates (the fruit fly and the nematode) and vertebrates (zebrafish) for drug screening. The small size, high fecundity, and experimental tractability of these animals enable cost-effective and rapid screening of numerous compounds.

Automating R&DAutomating R&D
by Kimberly S. Cleaves

PDF version (152 KB PDF)
Drug discovery is now predicated on automated instrumentation, experimentation, and analysis. For example, the race to map the human genome helped drive the need for robotic and automated methods in gene sequencing and data handling. R&D in pharmaceuticals, genomics, proteomics, and molecular diagnostics relies on automated technologies.

America’s biotech heartlandAmerica’s biotech heartland
by Randall C. Willis

PDF version (108 KB PDF)
Milwaukee and Madison are just two of the centers of scientific excellence in Wisconsin, which is rapidly expanding its role in America’s biotech industry.


The Tool Box
Lipomic profiling, profiled
(72 KB PDF)
by Amy Adams and Jan Kingsbury
In functional genomics, toxicology, and drug discovery, knowing the full breadth of lipid metabolism can help.

Ready to Read (64 KB PDF)
Mavericks, Miracles, and Medicine
Reviewed by Randall C. Willis
[Buy from]

Product Info Now (html)

On the Calendar
DDT 2004
(56 KB PDF)
A Boston perennial for drug scientists

Content in Context
Watercooler talk (32 KB PDF)
by Ann M. Thayer

New and Noteworthy (88 KB PDF)
IBM activities • Inhibiting autoimmunity • On the critical path • FDA: Increasing interaction, selectively • Meeting for minds • Profiling Parkinson’s • SPEEDy siRNA • Delivering a nuclear payload

Focus on Business

Marketplace, deals, and people (56 KB PDF)

Looking for value (56 KB PDF)
by Randall C. Willis
In developing next-generation technology platforms, many biotech companies have forgotten to generate equity.

Blockbuster model breaking down (60 KB PDF)
by Ann M. Thayer
Pharma industry reaches new sales peak, despite rising costs and bigger challenges for drug R&D.

People and Perspectives
Moving from drugs to medicine
(48 KB PDF)
by Randall C. Willis
By following a systems approach, researchers and clinicians move toward predicting and preventing disease.

Diseases and Disorders
Cystic fibrosis: Pipeline of promise
(68 KB PDF)
by Linda Richards
After more than a decade of work, drugs help, but a real cure is still a decade away

Rules and Regulators
Arrays and the FDA
(76 KB PDF)
by David Filmore
A new product from Roche Diagnostics is testing the regulatory waters for diagnostic microarrays.

Clinical Trials Track
Assessing antisense
(60 KB PDF)
by David Filmore
An NDA withdrawal signals another setback, but hope remains for next-generation drugs.

Applications Notebook
Mass identification
(156 KB PDF)
Dale H. Patterson and Matthew Willetts
Advancing protein and biomarker discovery with MALDI-TOF/TOF MS technology

Sites and Software
The PDA: Making headway into a new frontier (72 KB PDF)
by Kimberly S. Cleaves
Life sciences in the palm of your hand